EDIT vs ROK · rev $32.3M vs P/E 48, rev $8.34B
Editas Medicine Inc (EDIT) versus Rockwell Automation Inc (ROK) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Rockwell Automation Inc (ROK) is a specialty industrial machinery company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported ROK revenue for 2025-09-30 was $8.34B. Net income was $749.0M. Revenue was up 0.9% from 2024-09-30 to 2025-09-30. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
EDIT currently screens at market cap $375.2M. ROK currently screens at market cap $51.04B and trailing P/E 47.5.
Not investment advice. Open the EDIT and ROK stock pages for the full models.
Not investment advice.